PLIANT THERAPEUTICS INC (PLRX)
US7291391057 - Common Stock
What's going on in today's after hours session
Curious about the stocks that are showing activity after the closing bell on Monday?
Pliant Therapeutics to Participate in Upcoming Investor Events
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
INTEGRIS-PSC featured in an oral late breaker presentation SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc....
PLRX Makes Notable Cross Below Critical Moving Average
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Pliant Therapeutics to Participate in the Stifel Healthcare Conference
Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs
Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs
Former Bristol Myers Squibb Global Medical Affairs Lead brings over 25 years of experience to Pliant SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE...
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on September 30, 2024 it...
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024
Pliant Therapeutics to Participate in Upcoming Investor Events
Pliant Therapeutics to Participate in Upcoming Investor Events
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and...
Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024
Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024
SOUTH SAN FRANCISCO, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in...
PLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q2 2024
PLRX stock results show that Pliant Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
PLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pliant Therapeutics (NASDAQ:PLRX) just reported results for the second quarter ...
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Positive data from a 12-week Phase 2a PET imaging trial demonstrated reduced total lung collagen, improved FVC and reduced cough severity in IPF patients...
Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that Keith Cummings, M.D., Chief...
Pliant Therapeutics Enters Oversold Territory (PLRX)
7 Biotech Stocks to Buy on the Dip: June 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.
Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
SOUTH SAN FRANCISCO, June 13, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the...
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on June 10, 2024, it...
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
SOUTH SAN FRANCISCO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in...
Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader...
Commit To Purchase Pliant Therapeutics At $10, Earn 16% Using Options
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
12-week treatment with Bexotegrast 160 mg resulted in reduction of total lung collagen as measured by PET imaging, compared to an increase on placebo ...